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The absence of fragile-X mental-retardation protein (FMRP)
results in fragile-X syndrome. Two other fragile-X-related (FXR)
proteins have been described, FXR1P and FXR2P, which are
both very similar in amino acid sequence to FMRP. Interaction
between the three proteins as well as with themselves has been
demonstrated. The FXR proteins are believed to play a role in
RNA metabolism. To characterize a possible functional role of
the interacting proteins the complex formation of the FXR
proteins was studied in mammalian cells. Double immuno-
fluorescence analysis in COS cells over-expressing either FMRP
ISO12}FXR1P or FMRP ISO12}FXR2P confirmed heterotypic
interactions. However, Western-blotting studies on cellular
homogenates containing physiological amounts of the three
proteins gave different indications. Gel-filtration experiments
under physiological as well as EDTA conditions showed that the
FXR proteins were in complexes of " 600 kDa, as parts of
INTRODUCTION
Fragile-X syndrome is characterized by mental retardation,
macro-orchidism and various abnormal somatic signs [1]. The
disease results from the lack of expression of the FMR1 gene and,
subsequently, of the encoded protein fragile-X mental-retar-
dation protein, or FMRP [2,3].
FMRP (70–80 kDa) is a cytoplasmic RNA-binding protein
that can interact with RNA homopolymers and fetal brain
mRNAs [4–6]. Indeed, FMRP contains two hnRNPK homology
(KH) domains and an RGG amino acid motif (RGG box), both
characteristics of RNA-binding proteins [7,8]. The RNA-binding
activity is linked directly to the function of FMRP, as a mutation
in the second KH domain, causing an I304!N substitution, has
been found in a patient with a severe form of fragile-X syndrome
[9]. Although crystallographic data indicate that this mutation
causes misfolding of the KH domain [10], impaired RNA binding
of the mutated FMRP I304N has been observed only in high salt
conditions [11,12]. Moreover, the majority of FMRP co-frac-
tionates with polyribosomes isolated from different tissues
[13–16]. Studies performed with EDTA, which dissociates the
polyribosomes, indicate that FMRP is part of a messenger
ribonuclear protein (mRNP) particle with a sedimentation value
of 60 S [17,18]. However, the interaction of FMRP with the large
ribosomal subunit has also been proposed [16]. FMRP contains
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messenger ribonuclear protein (mRNP) particles associated with
polyribosomes. Salt treatment shifted FMRP, FXR1P and
FXR2P into distinct intermediate complexes, with molecular
masses between 200 and 300 kDa. Immunoprecipitations of
FMRP aswell as FXR1P from the dissociated complexes revealed
that the vast majority of the FXR proteins do not form
heteromeric complexes. Further analysis by [$&S]methionine
labelling in io followed by immunoprecipitation indicated that
no proteins other than the FXR proteins were present in these
complexes. These results suggest that the FXR proteins form
homo-multimers preferentially under physiological conditions in
mammalian cells, and might participate in mRNP particles with
separate functions.
Key words: fragile-X syndrome, FXR interaction, poly-
ribosomes, protein aggregation.
both nuclear-localization signals and nuclear-export signals
(NES) and, therefore, it might be involved in the nucleo-
cytoplasmic transport of as-yet-unknown RNAs [15,19,20].
Two other fragile-X-related (FXR) proteins have been
identified, FXR1P (70–80 kDa) and FXR2P (E 95 kDa), which
are very similar to FMRP (E 60% amino acid identity, with
regions of 90% identity) [21,22]. Consequently, FXR1P and
FXR2P contain all the known functional domains of FMRP, are
cytoplasmic RNA-binding proteins [21,22] and co-fractionate
with polyribosomes too [16–18,23]. FMRP, FXR1P and FXR2P
(the FXR proteins) are divergent only in their C-terminal regions.
Both in itro binding studies and the yeast two-hybrid system
have revealed that the FXR proteins interact with themselves
and with each other [21,22]. It has been shown that a coiled-coil
domain, which is similarly present in the conserved N-termini of
the three proteins (amino acids 171–211 in FMRP), is important
for FXR oligomerization [16]. However, comparative expression
studies, resulting in different tissue and cellular and intracellular
distributions of the FXR proteins, suggest that they might have
an independent function [23–25]. Interestingly, in adult brain the
three proteins are co-expressed in the cytoplasm of differentiated
neurons [23,25].
In order to understand the pathogenesis found in fragile-X
syndrome, it is necessary to establish whether the FXR-protein
heteromeric-complex formation demonstrated previously in itro
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[22] also occurs in mammalian cells. In the present study, we
show that FMRP, FXR1P and FXR2P are associated with large
RNA–protein particles, mainly as homo-multimers with mol-
ecular masses of 200–300 kDa.
EXPERIMENTAL
Cell culture and subcellular fractionations
Lymphoblastoid cells were grown in 5% CO
#
with RPMI 1640
medium supplemented with 10% fetal calf serum (FCS) and
antibiotics. HeLa cells were grown in 5% CO
#
with Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10%
FCS and antibiotics. Cells were washed twice with ice-cold PBS
and homogenized in a buffer containing 20 mM Tris}HCl, pH
7.4, 100 mM KCl, 2.5 mM MgCl
#
, 1 mM dithiothreitol, 10 lg}ml
RNasin (Pharmacia), 0.5% Nonidet P-40 and a cocktail of
protease inhibitors (Complete from Boehringer Mannheim). Cell
lysates were then homogenized by passage through hypodermic
needles and centrifuged at 10000 g to obtain a cytoplasmic
supernatant. For KCl or EDTA treatments, either KCl (500 mM)
or EDTA (25 mM) was added to a portion of cytoplasmic lysate,
and the samples were kept on ice for 30 min prior to gel filtration
and immunoprecipitation.
Gel filtration, immunoprecipitation and Western blotting
Weused aPrecisionColumnPC3.2}30 pre-packedwith Superdex
200 in a SMART system (Pharmacia) to determine by gel
filtration the molecular mass of FMRP [14], FXR1P and FXR2P.
The optimal range for separation of globular proteins in this
column is 10–600 kDa, with an exclusion limit of 1300 kDa. In
order to calibrate the column and to determine the molecular
masses of the eluting fractions, three protein markers were
applied in a physiological buffer giving the following results :
ferritin (440 kDa) in fraction 11, catalase (240 kDa) in fraction
16 and BSA (68 kDa) in fractions 19–20. The markers were
tested in other buffer conditions (500 mM KCl), giving analogous
retention times. Before running, the column was equilibrated for
30 min in each corresponding buffer ; 40–60 ll of cytoplasmic
lysate was injected into the SMART system and the protein
profile was monitored at 280 nm with a flow rate of 50 ll}min.
Fractions (50 ll each) were collected separately.
Immunoprecipitations were carried out overnight at 4 °C in
buffer containing either 20 mM Tris}HCl, pH 7.4, 500 mM KCl,
2.5 mM MgCl
#
, 1 mM dithiothreitol, or 20 mM Tris}HCl, pH
7.4, 100 mM KCl, 25 mM EDTA, 1 mM dithiothreitol, and
protease inhibitors (Complete). The antibodies were Ab734
against FMRP (1:100) [4], Ab1934 against the long FXR1P
isoform (1:100) [25], Ab2107 against both FXR1P isoforms
(1:100) and one against the 60 S ribosomal protein P0 (1:100;
Immunovision). Ab2107 was raised against a synthetic peptide
encompassing amino acids 483–500 of FXR1P. Protein A–
Sepharose beads (Pharmacia) were added for 3 h to bind and
recover the antibodies. The beads were washed four times with
the immunoprecipitation buffer.
Protein samples in Laemmli buffer [26] were separated on
SDS}polyacrylamide gels (either 10 or 7.5%), or electroblotted
on to nitrocellulose membranes (Schleicher and Schuell).
Immunodetection were made using the mouse monoclonal anti-
body 1C3 against FMRP diluted 1:2500 [27,28], Ab1934 (1:4000)
and Ab2107 (1:4000) against FXR1P and Ab1937 against
FXR2P (1:500) [25]. The secondary antibody was coupled to
peroxidase, allowing detection with the enhanced chemiluminesce
method (ECL kit, Amersham).
Immunoprecipitation of labelled proteins
HeLa cells growing exponentially in 75-cm# flasks were washed
in PBS. Subsequently, the cells were incubated overnight at 37 °C
in 5% CO
#
, in 7 ml of DMEM without the amino acids
methionine and leucine, supplemented with 2% dialysed FCS,
20 lCi}ml [$&S]methionine and 16 lCi}ml [$H]leucine. After 16 h
of labelling the cells were harvested by trypsinization. The cells
were homogenized and subjected to immunoprecipitation as
described above. The immunoprecipitated sample was separated
on either 7.5 or 10% acrylamide gel. The proteins present in the
gel were fixed in a solution containing 50% methanol and 7.5%
acetic acid. The gel was then dried and exposed with an
autoradiographic film (Kodak) for 4 days.
Transfections and immunofluorescence
COS cells were cultured in DMEM, containing 10% FCS, at
37 °C and 5% CO
#
. The day before transfection the cells were
seeded on glass coverslips. Transfections using 0.5 lg of DNA,
3 ll of Plus reagent (Gibco-BRL) and 2 ll of Lipofectamine
(Gibco-BRL) were performed as described by the manufacturer.
Cells were fixed for immunofluorescence 24 or 48 h after trans-
fection in 0.1 M PBS containing 3% paraformaldehyde (pH 7.3)
for 7 min at room temperature followed by a permeabilization
step in 100% methanol for 20 min. Primary and secondary
antibody incubations were performed for 60 min at room tem-
perature in blocking buffer containing PBS, pH 7.4, containing
0.15% glycine and 0.5% BSA (both from Fluka). The primary
antibodies were Ab1937 (1:200), Ab1934 (1:200), 1C3 (1:200),
a rabbit anti-tuberin antibody (ABTS, 1:400) [29] and a rabbit
anti-MTG8 antibody (Ab1499) [30]. The fluorescein-conjugated
anti-mouse secondary antibody and either the fluorescein- or the
rhodamine-conjugated anti-rabbit secondary antibodies were
used at 1:100 dilution (Dako). Images were captured using the
Power Gene FISH system on a Leica DMRXA microscope at
‹1000 magnification. Images were processed using a filter wheel
(Chroma Technology) and the Adobe PhotoShop software
package.
RESULTS
Interaction of the FXR proteins in transfected COS cells
The interaction between the FXR proteins was investigated in
transfected COS cells. An expression vector containing the full-
length cDNA of either FXR1 or FXR2 was co-transfected with
the expression vector containing FMR1 ISO12, a splice variant
of the FMR1 gene. After 48 h the corresponding proteins were
detected by double immunofluorescent staining using specific
antibodies.
The FMRP splice variant ISO12 lacks, as a result of a frame
shift, the C-terminal part of FMRP, including the NES and a
potentialRNA-binding domain (RGG box), whereas it maintains
all the other functional domains [27]. Like wild-type FMRP,
FMRP ISO12 can normally interact with FXR1P and FXR2P in
itro [16]. As a consequence of the absence of an NES, FMRP
ISO12 localizes in the nucleoplasm of single transfected cells
[27,28]. However, in all cells co-expressing FMRP ISO12 and
FXR2P we detected FMRP ISO12 in the cytoplasm (Figure 1A).
This change in FMRP ISO12 localization was also observed in
the presence of over-expressed FXR1P (results not shown).
Conversely, FXR2P (Figure 1B) and FXR1P did not change
their normal cytoplasmic localization in the presence of FMRP
ISO12.
We noticed that both the FXR1 and FXR2 expression vectors
produced very high amounts of the respective proteins, which
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Figure 1 FXR protein interaction in transfected COS cells
COS cells were double-transfected with expression plasmids encoding FMRP ISO12 (A) and
wild-type FXR2P (B). As a control, COS cells were double-transfected with expression plasmids
encoding FMRP ISO12 (D) and tuberin (E), FXR2P (G) and MTG8-ETO (H). In (C), (F) and (I)
the respective merged images are shown, as labelled.
were often detected as aggregates in the cytoplasm of the COS
cells. To exclude the possibility that the above-detected inter-
actions were due to non-specific protein precipitation, we per-
formed co-transfections with two unrelated proteins. We chose
tuberin (cytoplasmic) [29] and MTG8}ETO (nuclear) [30], be-
Figure 2 Distribution of the FXR proteins after gel permeation chromatography
HeLa cells were homogenized in low-salt (150 mM KCl ; A) and high-salt (500 mM KCl ; B) buffers. Subsequently the samples were separated by gel filtration, and each collected fraction was
tested for the presence of FMRP, FXR1P and FXR2P.
cause both contain interactive coiled-coil domains, like the FXR
proteins [16]. The nuclear localization of FMRP ISO12 was not
affected by co-expression of tuberin (Figures 1D and 1E,
respectively), nor did FXR2P interfere with the nuclear local-
ization of MTG8}ETO (Figures 1G and 1H, respectively).
We concluded that the detected interactions between FMRP
ISO12}FXR2P and FMRP ISO12}FXR1P were specific. Thus
the FXR proteins can form heterotypic interactions in an over-
expression mammalian cellular system, confirming previous data
obtained with purified proteins as well as with the yeast two-
hybrid system. In addition, we showed that wild-type FXR
proteins exercise a dominant effect on the localization of the
NES-mutated FMRP ISO12.
Gel-filtration analysis of FMRP, FXR1P and FXR2P
The predicted FXR complexes were further characterized in
lymphoblastoid and HeLa cells, where the endogenous expression
of FMRP, FXR1P and FXR2P has been demonstrated. Cellular
homogenates were separated on a Superdex 200PC precision
column using non-denaturing buffers and the collected fractions
were analysed for the presence of the three proteins by Western
blotting. To detect FXR1P we raised a new antibody (Ab2107),
which recognizes both the long and the short isoforms of FXR1P.
The initial fractionation performed in physiological buffer
showed that the majority of FMRP eluted in fractions 8 and 9
(Figure 2A), corresponding with the void volume of the column
and indicating protein complexes larger than 600 kDa. Similarly
to FMRP, the two major isoforms of FXR1P (long and short ;
Figure 2A) as well as FXR2P (Figure 2A) co-eluted in fractions
8 and 9. These results are in line with the notion that the FXR
proteins are detected mainly in polyribosomal fractions under
physiological conditions [13–16].
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Figure 3 FXR proteins immunoprecipitated in the presence of high salt
concentration (500 mM KCl)
HeLa cellular homogenate prepared in 500 mM KCl were subjected to immunoprecipitation (IP)
with either anti-FMRP antibodies Ab734 (lane 3), or anti-long FXR1P isoform antibodies Ab1934
(lane 6). The immunoprecipitated samples were tested sequentially by Western blotting for the
presence of FMRP (lanes 3A and 6A), long FXR1P isoform (lanes 3B and 6B), FXR2P (lanes
3C and 6C) and P0 protein (lanes 3D and 6D). Total protein extracts (E 10%) before and after
immunoprecipitation of FMRP (lanes 1 and 2, respectively) and of FXR1P (lanes 4 and 5,
respectively) were tested for the presence of FMRP, FXR1P, FXR2P and P0.
Figure 4 Immunoprecipitation of the [35S]methionine-labelled 200–300-
kDa complex
[35S]Methionine-labelled HeLa cellular homogenate prepared in 500 mM KCl were subjected to
immunoprecipitation with either anti-FMRP antibodies Ab734 (lane 1), or a mixture of the anti-
FXR1P antibodies Ab1934 and Ab2107 (lane 2). The same material was also immunoprecipitated
with anti-FXR1P pre-immune sera (lane 3). The asterisk indicates non-specific protein bands.
Next, gel-filtration analysis was performed in a buffer con-
taining 500 mM KCl. In the presence of salt, FMRP, FXR1P
and FXR2P eluted in fractions 14–18 (Figure 2B), corresponding
to molecular masses of E 200–300 kDa, as calculated from
marker proteins run under identical conditions. Although the
FXR proteins showed common dissociation profiles, they eluted
in slightly different fractions. The majority of FMRP as well as
the long FXR1P isoform were detected in fraction 16 (cor-
responding with the elution profile of the protein marker catalase,
with a molecular mass of 240 kDa; Figure 2B). The short
FXR1P isoform was detected in fractions 18 and 19 (Figure 2B).
Finally, FXR2P was detected mainly in fraction 15 (Figure
2B). An internal molecular-mass marker, BSA (69 kDa), eluted
in fractions 18–21. With the exception of the short isoform of
FXR1P, we could barely detect the three proteins in those
fractions.
The presented results were obtained in repeated experiments
(nfl 5) using homogenates of lymphoblastoid as well as HeLa
cells. They indicated that FMRP, FXR1P and FXR2P could be
released from the polyribosomes [14,17] as intermediate com-
plexes of 200–300 kDa rather than as monomers. In addition,
the three FXR proteins eluted clearly in distinct fractions.
Biochemical characterization of the intermediate complexes
(200–300 kDa)
The finding that FMRP and FXR1P were in fractions distinct
from those containing FXR2P raised uncertainty as to whether
FXR hetero-multimers exist in living cells. Moreover, the precise
co-fractionation of FMRP with the long FXR1P isoform (Figure
2B) might have been caused by either a direct interaction of the
two proteins or the fractionation of two independent complexes
with fortuitously similar sizes.
To answer this point, immunoprecipitation of FMRP were
performed in the presence of 500 mM KCl using specific anti-
bodies against FMRP (Ab734) [4]. The immunoprecipitated
sample (Figure 3, lane 3) was analysed sequentially by Western
blotting for the presence of FMRP, FXR1P, FXR2P and the
protein P0. The latter is a component of the 60 S ribosomal
subunit. An aliquot corresponding to 10% of the cellular
homogenate before and after immunoprecipitation was also
tested for visual comparison (Figure 3, lanes 1 and 2, respectively).
It was found that the majority of FMRP was depleted from the
starting homogenate and recovered in the immunoprecipitated
fraction (Figure 3, lane 3A). Detectable amounts (E 10%) of the
long FXR1P isoform (Figure 3, lane 3B) as well as FXR2P
(Figure 3, lane 3C) were also co-precipitated. The protein P0
failed to co-precipitate with FMRP under these conditions
(Figure 3, lane 3D).
The equal intensities of the signals for FXR1P and FXR2P,
before and after immunodepletion of FMRP, confirm that the
majority of FMRP, FXR1P and FXR2P does not interact and
that only a few of the FXR proteins form hetero-multimers.
We further analysed the composition of the salt-dependent
intermediate complexes by immunoprecipitating the long isoform
of FXR1P with an antibody that recognizes specifically this
isoform (Ab1934) [25]. As above, the immunoprecipitated sample
was analysed sequentially for the presence of FMRP, FXR1P,
FXR2P and P0. Whereas FXR1P was recovered efficiently in the
immunoprecipitated fraction (Figure 3, lane 6B), only small
amounts of FMRP (E 10%) were co-precipitated (Figure 3, lane
6A). No co-precipitation of FXR2P could be detected in that
sample (Figure 3, lane 6C). Unfortunately, we could not perform
similar analysis on the FXR2P immunoprecipitate, since the
antibodies against FXR2P [25] were not as effective in immuno-
precipitation experiments (results not shown).
The immunoprecipitation of two out of three FXR proteins
resulted in a similar pattern of interactions. Since the presence of
salt does not affect the formation of FXR hetero-multimers in
itro [22], these results demonstrate that FMRP, FXR1P and
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Figure 5 Immunoprecipitation in low-salt buffer plus EDTA
HeLa cellular homogenates prepared in 25 mM EDTA were subjected to immunoprecipitation (IP)
with either anti-FMRP antibodies Ab734 (lane 3) or anti-protein P0 (lane 6). The
immunoprecipitated samples were tested sequentially for the presence of FMRP and P0. Total
protein extracts (E 10%) were also tested for the presence of the two proteins before and after
immunoprecipitation of FMRP (lanes 1 and 2) and P0 (lanes 4 and 5) respectively.
FXR2P exist in living cells mainly as homo-multimeric com-
plexes. As these experiments do not exclude the presence of other
proteins in these complexes, we investigated this possibility by
performing immunoprecipitation studies on HeLa cells labelled
in io with [$&S]methionine. The autoradiograph of the gel
was then analysed to detect additional co-immunoprecipitated
proteins.
Immunoprecipitation of FMRP (in 500 mM KCl) resulted in
the isolation of a close set of bands with molecular masses of
70–80 kDa (Figure 4, lane 1), most likely corresponding to the
different splicing isoform of FMRP. No co-immunoprecipitation
of additional proteins was detected in this sample. A parallel
immunoprecipitation of FXR1P (Ab1934}2107) demonstrated
only the presence of the long and short FXR1P isoforms (Figure
4, lane 2). The lower bands visible in the autoradiograph
were not specific as they were obtained with the correspondent
pre-immune antibodies too (Figure 4, lane 3). Either limits of
detection, or timing of interactions, might cause the absence of
co-immunoprecipitation of the FXR proteins, since we examined
here newly synthesized proteins.
Biochemical characterization of the large EDTA-dependent
complex
The addition of 5–25 mM EDTA dissociates the polyribosomes
and releases FMRP in complexes with a sedimentation coefficient
of 60 S [13,15,16]. Controversially, it has been shown that either
FMRP can physically associate with the 60 S ribosomal subunit,
or it is part of a large mRNP particle with the same sedimentation
coefficient [17,18]. Therefore, we used EDTA treatment (25 mM)
to investigate the composition of these large RNA–protein
particles containing the FXR proteins [13,16,23].
In gel-filtration experiments, the three proteins were detected
in fractions 7 and 8, corresponding to complexes larger that
600 kDa (results not shown). This result was similar to what was
seen in physiological buffer (Figure 2A).
In Figure 5 it is shown that the efficient immunoprecipitation
of the ribosomal protein P0 from a HeLa cellular homogenate in
the presence of 25 mM EDTA (lane 6) resulted in the co-
immunoprecipitation of E 5% of the total amounts of FMRP.
For FXR1P similar results were obtained (not shown). Thus
FMRP and FXR1P are not in the same complex as P0 and not
directly bound to ribosomes.
Figure 6 Detection of additional (co-precipitated) proteins in the FXR1P
immunoprecipitate
[35S]Methionine-labelled HeLa cellular homogenates prepared in a buffer containing either
500 mM KCl (lane 1) or 25 mM EDTA (lanes 2 and 3) were subjected to immunoprecipitation
using anti-FXR1P antibodies (mixed Ab1934 and Ab2107) recognizing the long (L) and short
(S) isoforms (lanes 1 and 2) and pre-immune sera (lane 3). The longer arrows indicate the
bands of the co-precipitated proteins. The asterisk indicates non-specific protein bands.
Interestingly, the immunoprecipitation of the long and short
FXR1P isoforms from [$&S]methionine-labelled HeLa cells
caused the co-immunoprecipitation of, at least, three additional
proteins. These proteins showed approximate molecular masses
of 40, 50 and 100 kDa (Figure 6, lane 2). Importantly, the three
proteins were co-immunoprecipitated neither by the pre-immune
sera under the same EDTA treatment (Figure 6, lane 3), nor by
antibodies against FXR1P in the presence of 500 mM KCl
(Figure 4, lane 2, and Figure 6, lane 1). This suggests that
FXR1P and the three new proteins are components of the same
large complex.
We concluded that, after dissociation of the polyribosomes,
the vast majority of FMRP as well as FXR1P is present in large
complexes, which do not include the ribosomal protein P0.
Therefore, we support the notion that the FXR proteins are
associated with the polyribosomes as mRNP particles rather
than as components of the large ribosomal subunit.
DISCUSSION
FMRP, FXR1P and FXR2P (FXR proteins) can interact in itro
with themselves and with each other [22] ; however, the physio-
logical role of this multimerization is unclear. The observations
we describe here indicate that the vast majority of the FXR
proteins exist in cultured cells as homo-multimers rather than
hetero-multimers. These multimers have well-defined molecular
masses (E 200–300 kDa) and are contained within larger RNA–
protein particles. Therefore, it is possible that the FXR in-
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termediate complexes might regulate cellular processes such as
translation and maintenance of mRNA stability.
Several mRNA-binding proteins are present as multimers
within mRNP particles [31–33]. Dimerization can be either
essential for translation activity, as demonstrated for the RNA-
binding protein La [34], or important for RNA binding, as
demonstrated for Xenopus p54}56 proteins [35]. The FXR
proteins are connected with the polyribosomes in an RNA-
dependent manner [14,15,17]. Most likely, they are components
of polyribosome-associated mRNP particles [17,18,23]. We show
here that salt treatment shifts the FXR proteins from these large
complexes into distinct intermediate complexes of 200–300 kDa.
The molecular masses of these complexes are 3–4 times greater
than those of the FXR monomers (FMRP and the large FXR1P
isoform are E 70–80 kDa, FXR2P is E 95 kDa). In addition,
immunoprecipitation of FMRP (and FXR1P) from [$&S]-
methionine-labelled HeLa homogenates (in 500 mM salt) results
in the visualization of FMRP (and FXR1P), but not additional
proteins. Taken together, these observations indicate that
FXR proteins might be incorporated in those mRNP particles
as homo-multimers.
Previous experiments showed approximately similar levels of
FXR homo- and hetero-multimers, both in itro and in the yeast
two-hybrid system [22]. By Western blotting using specific
antibodies we compared the presence of the three proteins in
FXR immunoprecipitated samples in mammalian cells. We
reproducibly found that only E 10% of the total FMRP (and
FXR1P) amounts can form FXR hetero-multimers in mam-
malian cultured cells. Purified FMRP interacts with FXR1P and
FXR2P via a predicted coiled-coil domain present in the N-
terminal region (amino acids 171–211) [16]. FXR1P and FXR2P
have similar coiled-coil motifs (75% amino acid identity with
FMRP), which are also in their N-termini, and which are
important for interaction between the FXR proteins [16]. How-
ever, it is not clear whether or not these domains recognize
unique sequences within FMRP, FXR1P and FXR2P. It has
been proposed from crystallographic studies that coiled-coil
motifs interact with each other, forming a-helical structures. It is
therefore possible that the high amino acid similarity between the
three proteins is responsible for their strong association in itro.
If so, non-physiological interactions could occur readily when
the FXR proteins are brought together in high concentrations.
This would explain the interactions that we detected specifically
between the FXR proteins in an over-expressing cellular system
(Figure 1).
The hypothesis that FMRP might associate preferentially with
itself rather than with FXR1P and FXR2P is supported by other
observations. Firstly, Feng et al. [18] characterized the association
of FMRP with FXR2P in lymphoblastoid cells of a fragile-X
patient who had an amino acid substitution (I304N) in the
secondKHdomain ofFMRP [18]. FMRP I304N fails to associate
with polyribosomes and is incorporated in EDTA-resistant
particles with smaller sizes. Despite the fact that FXR2P and
FMRP I304N can normally interact in itro as well as in the yeast
two-hybrid system [16], FXR2P is not present together with
FMRP I304N in those abnormal particles. Secondly, we showed
recently that FMRP shuttles between cytoplasm and nucleo-
plasm, whereas FXR2P shuttles between cytoplasm and nu-
cleolus, suggesting that FMRP and FXR2P have distinct cellular
routes as well as different targets in the nucleus [36]. Thirdly,
comparative expression studies showed that each of the three
FXR genes}proteins have independent expression as well as
cellular distribution in tissues like muscle, fetal brain and testis
[23–25]. These arguments indicate that no functional interactions
between the FXR proteins exist in io.
It has been proposed that FMRP associates with the 60 S
ribosomal subunit via protein–protein interaction (in 5 mM
EDTA) [16]. In contrast, other reports strongly indicate a non-
association of the FXR proteins with this subunit (in 25 mM
EDTA) [17,18]. In our experimental conditions (25 mM EDTA),
the complete immunoprecipitation of the protein P0, a 60 S
ribosomal component, results in the co-immunoprecipitation of
E 5–10% of FMRP and FXR1P. These results confirm that the
majority of the FXR proteins rely in the proposed mRNP
particles [17,18], and associate via these particles with the
ribosomes.
It is becoming clear that a fundamental step in understanding
the function of the FXR proteins will be the definition of the
RNA and protein composition of these EDTA-resistant
complexes. Here we show the initial characterization of three
new proteins of E 40, 50 and 100 kDa, which co-precipitate with
FXR1P (Figure 6).
Further experiments are needed to characterize the protein
compositions of the high-molecular-mass complexes in which the
FXR proteins participate and the nature of their RNA targets.
New information will contribute to the understanding of the
pathogenesis in fragile-X patients as well as the mechanisms of
RNA transport and translation in general.
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